January 29 – 31 2019

Boston, MA

 

 

The 2018 DNA Damage Response Therapeutics Summit was the first industry-dedicated meeting focused on identifying the next generation of DNA damage response therapeutics, achieving efficacy across a range of contexts, optimizing synthetic lethal screening techniques and exploiting key targets of mechanisms of resistance.

Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more shared their insights and lessons learned, collectively enabling the community to:

  • Therapeutically Exploit Synthetic Lethal Interactions for Targeted Cancer Therapy
  • Optimize the Discovery, Clinical Development & Commercialization of Novel Cancer Therapies Based on the Genetic Concept of Synthetic Lethality
  • Leverage Advances in DNA Sequencing and CRISPR-Based Target Discovery to Generate Breakthrough Medicines

Download the 2018 Full Event Guide here.

Testimonials from our Past Events in the Cell and Viral Immunotherapy Space:

“Overall an excellent program with topical presentations and great opportunities to network with leaders in the field. The fact that it was a very focused meeting with high level people made such interactions possible and made it hugely valuable.”

Virttu Biologics


This Summit is for:

  • Biotech
  • Large Pharma
  • Academics Looking to Network with Industry
  • CRISPR & RNA Screening Companies
  • CROs
  • Model Developers
 Brochure
Media Partner